Form4insider filings, from the source

SEC Form 5 · accession 0000899243-19-003099

Dicerna Pharmaceuticals Inc · DRNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Douglas Fambrough
Officer — Chief Executive Officer · Director
Period of report
Dec 31, 2018
Accepted (ET)
Feb 8, 2019 · 9:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001399529

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (right to buy)F3$16.30Aug 31, 2018G200,000D—Apr 16, 2024Common Stock200,000271,900D
Employee Stock Option (right to buy)F3$16.30Aug 31, 2018G200,000D—Apr 16, 2024Common Stock200,00071,900D
Employee Stock Option (right to buy)F1,F3$16.30Aug 31, 2018G200,000A—Apr 16, 2024Common Stock200,000200,000I
Employee Stock Option (right to buy)F2,F3$16.30Aug 31, 2018G200,000A—Apr 16, 2024Common Stock200,000200,000I

Explanation of responses